共 228 条
[1]
Rosenbloom BE(2013)Gaucher disease: a comprehensive review Crit Rev Oncog 18 163-75
[2]
Weinreb NJ(2006)Heterozygosity for a Mendelian disorder as a risk factor for complex disease Clin Genet 70 275-82
[3]
Sidransky E(2012)Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis Blood 119 4731-40
[4]
Lo SM(2008)A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase Am J Hematol 83 890-5
[5]
Choi M(2012)Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years Br J Haematol 158 528-38
[6]
Liu J(2006)The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review Health Technol Assess 10 iii-iv
[7]
Jain D(2012)The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders Health Technol Assess 16 1-543
[8]
Boot RG(2008)Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring J Inherit Metab Dis 31 319-36
[9]
Kallemeijn WW(1989)Prediction of severity of Gaucher’s disease by identification of mutations at DNA level Lancet 2 349-52
[10]
Weinreb NJ(1997)Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement Skeletal Radiol 26 687-96